Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Safety and Efficacy of Acetyl-leucine in Post-stroke Ataxia
NCT07275749Phase 3Recruiting
- Sponsor
- Kafrelsheikh University
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ataxia comparing acetyl-leucine with placebo (2 arms). Primary endpoints: Berg Balance Scale at 90 days and Rate of participants who suffered from treatment-related side effects at 90 days. Started Dec 2025; status: recruiting.
02
Drugs
acetyl-DL-leucine
03
Conditions
ataxia
Beyond the preview
Go deeper on NCT07275749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275749.